COMP <GO>
ASND vs MRK // EV/EBITDA & P/E VALUATION
Ascendis Pharma A/S Ordinary Share (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ASND 4
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $251.27 (-0.68%) • MKT CAP: $16.67B
valuation
21.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASND VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASND | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 20.70% | -10.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 15.3x | +5.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 3.42% | -1.21 | MRK | /fcf-yield <GO> |
| Operating Margin | 13.90% | 34.30% | -20.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 28.10% | -17.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 12.10% | 1.30% | +10.80 | ASND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 5.19 | -1.45 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ASND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.8 | 56.9 | +7.97 | ASND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.92 | +0.06 | ASND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 18.4x | +9.20 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.67B | $361.02B | -$344.35B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASND REV | MRK REV | ASND GROSS % | MRK GROSS % | ASND FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $65.01B | — | 74.8% | — | $12.36B |
| FY 2024 | — | $64.17B | — | 76.3% | — | $18.10B |
| FY 2023 | — | $60.12B | — | 44.0% | — | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASND // BETA 0.98
MRK // BETA 0.92